A Study On The Risks Of Merger And Acquisition Of Pharmaceutical Enterprises

In the last several years,with the quickly development of China's economy,mergers and acquisitions have become an effective way for the rapid development of enterprises.In the context of global economic integration,the wave of mergers and acquisitions has been formed.With the increase of population and the increasing trend of population aging,the pharmaceutical industry in China has developed rapidly.On the one hand,under the reform of China's economic system,a lot of encouragement and support policies have been given to the medical and health industry,which has brought unprecedented opportunities for the development of the whole medical industry.On the other hand,with the increasing demand for medicine and the rising of medical enterprises,the market competition of medical industry is becoming more and more intense.Enterprises can only maintain their market share through their own reform and transformation.In this context,medical enterprises through mergers and acquisitions to overcome their own accumulation through mergers and acquisitions to overcome the limitations of the traditional progressive development.At present,a more popular means of absorbing merger and acquisition in the domestic capital market is the form of merger and merger of exchange stock.Facing the huge competition pressure of the same industry in pharmaceutical industry,it is an inevitable choice for the pharmaceutical listed companies to absorb shares and merge in the pharmaceutical industry.At the same time,in such a complex background,how to seize opportunities and identify risks and meet challenges is becoming a hot topic in academic circles and society.Therefore,this research is based on M & A in pharmaceutical industry,in order to provide reference for the stable development of our pharmaceutical industry.The research in this paper has high theoretical value and practical value.This paper takes Guangzhou pharmaceutical convertible merger of Baiyun Mountain as a case study,the main reason is that the two companies are gphl subsidiary of the listed company,between the two is very typical value of horizontal merger,merger case study,among the two successful mergers and acquisitions,the overall market can push gphl.Based on the theory of M & A and M & a risk,this paper first introduces the general situation of Guangzhou pharmaceutical and Baiyun Mountain enterprises,and the specific situations of the two exchange combinations.Then the risk composition and causes of the merger and acquisition of Baiyun Mountain in Guangzhou pharmaceutical industry are elaborated in detail in order to provide effective suggestions for the prevention strategy of upgrading the merger risk.From the perspective of mergers and acquisitions in pharmaceutical industry,this paper interprets and analyzes the case of Guangzhou pharmaceutical swap and merger and merger of Baiyun Mountain.It is found that although some risks have been identified in the merger process,it is still not comprehensive.The integration of China's pharmaceutical industry is indeed challenging and difficult.A comprehensive analysis of potential risks in the merger,to fully consider the cultural integration and innovation of enterprise personnel inside the main business;at the same time,but also a comprehensive analysis of the influence of the external market factors of enterprise and industry,and For the purpose of studying this topic,we use literature research method and empirical analysis method,through collecting valuable information,sorting out,summarizing,summarizing,and providing reference value for writing this thesis.By using the empirical analysis method,the performance of Guangzhou pharmaceutical industry before and after merger and acquisition is analyzed in detail.In order to reduce the risk of mergers and acquisitions among the various industries in China,a reasonable and practical strategy to prevent mergers and acquisitions is put forward.